Avidity Biosciences, Inc. ran experiments to evaluate how well local AI models could review a synthetic GxP audit trail, including scoring against a matched random baseline.

As of February 27, 2026, Avidity Biosciences is now a Novartis Company. See full details on the completed acquisition here: https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy For further information and updates, please visit the Novartis US website (www.novartis.com/us-en/). Please note that select jobs will continue to be available on this channel.